We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?
Read MoreHide Full Article
Sage Therapeutics, Inc. (SAGE - Free Report) shares soared 11.8% in the last trading session to close at $37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.1% loss over the past four weeks.
Last week, the company announced that it will present data from the phase II LUMINARY study which is evaluating SAGE-718 in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease. Data from the same showed that treatment with SAGE-718 was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in the given patient population. This might have been driving the share price rally.
This company is expected to post quarterly loss of $2.15 per share in its upcoming report, which represents a year-over-year change of -31.1%. Revenues are expected to be $4.44 million, up 181.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sage Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.
Sage Therapeutics, Inc. is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Revolution Medicines, Inc. (RVMD - Free Report) , finished the last trading session 0.6% higher at $25.65. RVMD has returned 40.3% over the past month.
For Revolution Medicines, Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.61. This represents a change of -15.1% from what the company reported a year ago. Revolution Medicines, Inc. currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?
Sage Therapeutics, Inc. (SAGE - Free Report) shares soared 11.8% in the last trading session to close at $37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.1% loss over the past four weeks.
Last week, the company announced that it will present data from the phase II LUMINARY study which is evaluating SAGE-718 in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease. Data from the same showed that treatment with SAGE-718 was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in the given patient population. This might have been driving the share price rally.
This company is expected to post quarterly loss of $2.15 per share in its upcoming report, which represents a year-over-year change of -31.1%. Revenues are expected to be $4.44 million, up 181.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sage Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sage Therapeutics, Inc. is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Revolution Medicines, Inc. (RVMD - Free Report) , finished the last trading session 0.6% higher at $25.65. RVMD has returned 40.3% over the past month.
For Revolution Medicines, Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.61. This represents a change of -15.1% from what the company reported a year ago. Revolution Medicines, Inc. currently has a Zacks Rank of #4 (Sell).